Biotest AG

A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dat

The month of September started out quietly in terms of approvals, but submission activity continued at a smart pace. Rare diseases are prominent among the recent applications, which include a first-li

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AiPharma Joins Effort To Develop Fujifi

Myriad clinical trials are planned or are already under way around the world as pharma and biotech companies, universities and research organizations turn their focus to trying to find treatments for